HER2 Protein: Structural Basis of the Transmembrane Glycoprotein, Signaling Network, and Tumor-Targeted Therapy

Author: Senior Product Manager of UA Views：10

This article focuses on the protein structure and signaling regulation functions of human epidermal growth factor receptor 2 (HER2), systematically elaborating its composition as an EGFR family transmembrane glycoprotein comprising extracellular, transmembrane, and intracellular domains, as well as its activation characteristics in the absence of known ligands. It analyzes the differential downstream signals driven by HER2 forming heterodimers with family members across different cancer types, and explores the clinical association of HER2 overexpression with tumor aggressiveness and poor prognosis, along with targeted therapeutic strategies.

Recent Advances
Product Information

Recent Advances

HER2 Protein: Structural Basis of the Transmembrane Glycoprotein, Signaling Network, and Tumor-Targeted Therapy

Brief introduction: This article focuses on the protein structure and signaling regulatory functions of human epidermal growth factor receptor 2 (HER2), systematically describing its composition as an EGFR-family transmembrane glycoprotein—including the extracellular, transmembrane, and intracellular domains—and its activation characteristics in the absence of known ligands. It analyzes the differential downstream signals driven by HER2 forming heterodimers with family members across different cancer types, and discusses the clinical association of HER2 overexpression with tumor aggressiveness and poor prognosis as well as targeted therapeutic strategies.

I. Molecular Structure and Receptor Localization of HER2.

HER2 is a transmembrane glycoprotein in the epidermal growth factor receptor family that participates in cell proliferation and differentiation. Its abnormal expression or mutation is closely associated with the aggressiveness and poor prognosis of tumors such as breast cancer and gastric cancer. Structurally, HER2 is a transmembrane glycoprotein of the EGFR family, comprising an extracellular domain, a transmembrane region, and an intracellular tyrosine kinase domain. The extracellular domain consists of four subdomains responsible for dimerization; the transmembrane region helps localize the receptor; and the intracellular kinase domain initiates signal transduction. HER2 has no known ligand and often activates downstream pathways through dimers to promote cell proliferation, broadly participating in the occurrence and development of multiple cancers. This “ligand-free, dimerization-dependent” activation mode determines that HER2’s functional realization does not depend on the ligand-binding event itself, but on its assembly state with family members on the cell membrane——which also makes HER2 the family member with the strongest signal amplification capability in the HER family.

II. HER2 Signaling Pathways and Their Regulatory Roles in Cellular Processes.

HER2 signaling pathways play key regulatory roles in cell growth, survival, and differentiation. HER2 itself has no known direct ligand and mainly activates signal transduction by forming heterodimers with other members of the epidermal growth factor receptor family. In breast cancer, HER2 mostly forms heterodimers with HER3, significantly activating the PI3K/AKT and MAPK signaling pathways to promote cell proliferation and survival. HER2 expression in gastric cancer shows strong heterogeneity, forming dimers with HER3 and possibly other EGFR members, thereby enhancing tumor invasive capacity. In non-small cell lung cancer, HER2 mutations (such as exon 20 insertions) enable HER2 to activate signaling without ligands, promoting tumor development. In colorectal cancer, HER2 can dimerize with EGFR, affecting the efficacy of anti-EGFR drugs. In addition, some ovarian cancers also exhibit HER2 overexpression and dimer formation, participating in tumor progression. These different dimer forms reflect the complex mechanisms of HER2 action in multiple cancers.

An important biological principle can be distilled from this cancer-type distribution: the oncogenic potential of HER2 is not determined by a single fixed mechanism, but is shaped by the dimerization partners it selects in different tissue contexts. In breast cancer, the HER2/HER3 pairing dominates potent activation of the PI3K/AKT pathway; the expression heterogeneity in gastric cancer means that different cell clones within the same tumor may adopt different dimerization combinations; exon 20 insertion mutations in lung cancer bypass dimerization dependence and directly confer ligand-independent constitutive activity to the kinase domain; and HER2 dimerization with EGFR in colorectal cancer reveals the mechanism by which HER2 acts as a bypass activation node affecting the efficacy of other targeted drugs. Therefore, understanding HER2 signaling must be placed within specific cancer types and molecular contexts, rather than treating it as a single homogeneous driver event.

III. Interaction Patterns Between HER2 and EGFR Family Members.

HER2 can form homo- or heterodimers with EGFR family members, with heterodimers exhibiting stronger signaling activity. HER2/HER1 dimers enhance oncogenic signaling; HER3, though lacking kinase activity, possesses multiple phosphotyrosine sites, and HER2/HER3 dimers potently activate downstream pathways, commonly seen in breast and prostate cancer. HER2 can also dimerize with HER4; although the effect is weaker, it participates in mammary development and lactation. This interaction spectrum reveals a key structure-function logic: the kinase domain of HER3 lacks catalytic activity due to key residue substitutions, and its signal transmission relies entirely on the kinase activity of its dimerization partner; HER2 is precisely the family member with the strongest kinase activity and highest dimerization propensity. Their combination forms a complementary division of labor in which “HER3 provides multiple phosphotyrosine docking sites and HER2 provides catalytic activity,” which is the structural basis for the signaling activity of HER2/HER3 heterodimers far exceeding other combinations. The physiological role of HER2/HER4 dimers in normal mammary development suggests that HER2 signaling is not solely pathological; its fine regulation under physiological conditions likewise depends on specific dimerization pairings.

IV. Significance of HER2 in Tumor Biology and Targeted Therapeutic Strategies.

HER2 overexpression is common in 20% to 30% of breast cancers, promoting abnormal cancer cell proliferation and invasion and leading to poor prognosis. HER2-targeted drugs such as trastuzumab and neratinib can effectively block its signaling pathways and improve patient prognosis. HER2 abnormalities are also seen in gastric cancer, NSCLC, and other cancers, with drug resistance being a therapeutic challenge.

From a hierarchical perspective on therapeutic strategies, HER2-targeted interventions can be divided into three levels: at the extracellular receptor level, monoclonal antibodies block the dimerization interface by binding the extracellular domain and can recruit immune cells through antibody-dependent cell-mediated cytotoxicity; at the intracellular kinase level, small-molecule tyrosine kinase inhibitors block receptor autophosphorylation by competitively binding the ATP pocket; and at the antibody-drug conjugate level, the high membrane surface expression of HER2 is used as a delivery anchor to direct cytotoxic payloads into tumor cells. However, the emergence of drug resistance remains the core issue constraining long-term efficacy——its mechanisms involve bypass activation of HER2 downstream pathways, switching of dimerization partners, and structural changes in drug-binding epitopes, among multiple levels. This also explains why HER2-targeted therapy requires continuous development of new molecular formats and combination strategies rather than reliance on a single drug.

V. Conclusion.

As a transmembrane glycoprotein in the EGFR family with no known ligand and dimerization-dependent activation, HER2—by virtue of its three-module structure comprising an extracellular dimerization interface composed of four subdomains, a transmembrane localization region, and an intracellular tyrosine kinase domain; its signal output driven by forming differential heterodimers with partners such as HER3 and EGFR across different cancer types including breast, gastric, lung, and colorectal cancer; and its stable clinical association of overexpression with aggressiveness and poor prognosis—has become one of the most representative protein molecules in the field of solid tumor targeted therapy.

In basic research and targeted drug development related to HER2 protein, high-quality recombinant HER2 protein is a core tool for dissecting its domain functions, evaluating the binding activity of targeted drugs, and conducting dimerization mechanism studies. The His tag facilitates efficient purification via immobilized metal affinity chromatography and enables detection and capture via anti-His tag antibodies. To meet the needs of HER2 protein functional research and tumor-targeted drug development, Univ provides Her2/ErbB2 His Tag Protein, Human. This product is suitable for applications including binding activity analysis of HER2 with targeted antibodies and small-molecule inhibitors, studies of dimerization mechanisms mediated by the HER2 extracellular domain, in vitro screening and evaluation of HER2-targeted antibody-drug conjugates, and establishment and validation of HER2 protein immunoassay methods.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next